|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Carlos Manuel Buesa Arjol||Co-Founder, Chairman, CEO & Pres||58k||N/D||N/D|
|Mr. Enric Rello Condomines||Director of Operations, COO & CFO||N/D||N/D||N/D|
|Mr. Jordi Xaus Pey||Chief Scientific Officer||N/D||N/D||N/D|
|Mr. Xavier Perpinya Ribera||Head of Internal Audit & Compliance||N/D||N/D||N/D|
|Mr. Emili Torrell Cortada||Chief Bus. Devel. Officer||N/D||N/D||N/D|
|Ms. Neus Virgili Bernado||Chief Intellectual Property Officer||N/D||N/D||N/D|
|Dr. Michael Thomas Ropacki Ph.D.||Chief Medical Officer of CNS||N/D||N/D||N/D|
|Ms. Sonia Paloma Gutierrez Bezon||Chief of Clinical Operations||N/D||N/D||N/D|
|Dr. Saikat Nandi||Global Chief Bus. Officer||N/D||N/D||N/D|
|Dr. Ana Limon||Sr. VP of Clinical Devel. & Global Medical Affairs||N/D||N/D||N/D|
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
L'ISS Governance QualityScore di Oryzon Genomics S.A. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.